Grave's disease: Classical triad & response to treatment
نویسندگان
چکیده
منابع مشابه
Retrospective study of clinical course and treatment response in Graves’ disease [Persian]
In this report, the clinical course and treatment response of 210 patients with Grawes’ disease referred to the research institute for nuclear medicine were studied. The disease was more common in 3rd and 4th decades and more frequent in women (F/M=4). Treatment response with antithyroid drugs was about 50%, whereas 80% of the patients treated by I-131 showed positive response. There was ...
متن کاملRadioiodine treatment of Graves' disease - dose/response analysis.
The clinical outcome of 153 Graves' disease patients treated with a wide dose range of radioactive iodine-131 (RAI) was analyzed retrospectively. Six to nine months after the first dose of RAI 60 patients (39%) were hypothyroid (or rather thyroxine-substituted) and 26 (17%) were euthyroid, while 67 patients (44%) did not respond properly: in 32 (21%) their antithyroid drug (ATD) dose could be r...
متن کاملGraves' disease in children and adolescents: response to long-term treatment.
BACKGROUND Optimal treatment of Graves' disease in paediatric patients is still a matter of controversy. Antithyroid drugs, radioiodine and thyroidectomy are the three therapeutic options available. AIM To report our experience of long-term medical treatment and outcome of paediatric Graves' disease. METHODS A 5-y-long medical protocol was implemented in 20 children and adolescents with Gra...
متن کاملretrospective study of clinical course and treatment response in graves’ disease [persian]
in this report, the clinical course and treatment response of 210 patients with grawes’ disease referred to the research institute for nuclear medicine were studied. the disease was more common in 3rd and 4th decades and more frequent in women (f/m=4). treatment response with antithyroid drugs was about 50%, whereas 80% of the patients treated by i-131 showed positive response. there was no mea...
متن کاملGraves' disease development during sizofiran treatment.
It has been reported that various types of immunoactivators can induce Graves' disease. We describe here a case of Graves' disease during treatment with sizofiran, an immunoactivator. A 42-year-old woman who had previously been in an euthyroid state with Hashimoto's thyroiditis, experienced thyrotoxicosis during continuous administration of sizofiran as immunotherapy for endometrial carcinoma. ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Indian Journal of Medical Research
سال: 2020
ISSN: 0971-5916
DOI: 10.4103/ijmr.ijmr_2225_19